Rodríguez Paulo C, Ochoa Augusto C
Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Immunol Rev. 2008 Apr;222:180-91. doi: 10.1111/j.1600-065X.2008.00608.x.
Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy. L-arginine (L-Arg) is a conditionally essential amino acid that is fundamental for the function of T lymphocytes. Recent findings in tumor-bearing mice and cancer patients indicate that increased metabolism of L-Arg by myeloid derived suppressor cells (MDSCs) producing arginase I inhibits T-lymphocyte responses. Here we discuss some of the most recent concepts how MDSC expressing arginase I may regulate T-cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.
癌症患者的T细胞反应受损,这会降低癌症疫苗和其他形式免疫疗法的潜在治疗益处。L-精氨酸(L-Arg)是一种条件必需氨基酸,对T淋巴细胞的功能至关重要。最近在荷瘤小鼠和癌症患者中的研究结果表明,产生精氨酸酶I的髓源性抑制细胞(MDSC)对L-Arg的代谢增加会抑制T淋巴细胞反应。在此,我们讨论一些最新概念,即表达精氨酸酶I的MDSC如何在癌症和其他慢性炎症性疾病中调节T细胞功能,并提出可能的治疗干预措施以克服这种抑制作用。